NCT05282407View on ClinicalTrials.gov

A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

April 17, 2019

Study Completion Date

April 17, 2019

Conditions
Chronic Hepatitis B
Interventions
DRUG

Tenofovir disoproxil 245mg

1 tablet q.d. for 48 weeks

DRUG

Tenofovir disoproxil fumarate 300mg

1 tablet q.d. for 48 weeks

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

NCT05282407 - A phase4 Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B | Biotech Hunter | Biotech Hunter